mercklogoWith declarations that a new day is dawning in the treatment of hepatitis C, an FDA advisory panel unanimously approved the first of two new drugs to treat the stubborn liver infection.

“This changes the game completely,” says Dr. Victoria Cargill of the National Institutes of Health, acting chair of the FDA’s advisory committee. “I can look into the faces of the people (with hepatitis C) and offer them some hope.” 

“I can’t wait to get back and talk to my patients about it,” enthused panel member Dr. Barbara McGovern of Tufts Medical School in Boston.

(READ more of the story at NPR)

Leave a Reply